Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SESAME 2: Luxerm for Actinic Keratosis
NCT03511326Phase 4Completed
- Sponsor
- Galderma
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Galderma. Primary endpoint: Overall Subject Satisfaction at Week 12. Started Jun 2017; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03511326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511326.